Plain-English translation of NCT05052671 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether a new blood test that detects cancer DNA (ctDNA) can help doctors better understand how well pancreatic cancer treatment is working and predict how patients will do after surgery. Researchers will collect blood samples from about 50 patients at different points during their chemotherapy, radiation, surgery, and recovery period to see if this blood test can give important information about their cancer.
Currently, doctors have limited ways to tell if pancreatic cancer treatment is working before and after surgery. This study exists to see if this blood test could help doctors catch cancer earlier if it comes back, and understand which patients might benefit from different treatment approaches.
You likely qualify if…
You likely don't qualify if…
If you join this study, you'll receive your regular pancreatic cancer treatment — which may include 4 to 6 months of chemotherapy, radiation, and surgery — as planned. In addition, you'll have blood drawn at several regular time points during your treatment and during a 24-week monitoring period after surgery to test for cancer DNA. You'll also be followed up for 2 years to see how you're doing. The study uses your tumor tissue to create a personalized blood test just for your cancer.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Sponsor
University of Oklahoma
Collaborators
Natera, Inc.
Enrollment target
~50 participants
Started
May 2022
Primary completion
December 2026
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Lead Nurse
University of Oklahoma
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.